Diindolylmethane (DIM).

Broccoli sprouts supply glucobrassicin, which myrosinase converts to indole-3-carbinol, and I3C condenses to DIM under stomach acid. Taking the sprout material and supplemental DIM together means two entry points to the same molecule. A human study of DIM alongside Brussels sprouts made exactly that comparison in a toxicokinetic setting.

Sulforaphane and indole-3-carbinol both come from glucosinolate breakdown in cruciferous vegetables but they are chemically unrelated products. Sulforaphane works through Nrf2 activation and phase II enzyme induction; DIM acts largely as an aryl hydrocarbon receptor ligand affecting phase I. They converge on xenobiotic handling from opposite ends.

Calcium D-glucarate yields D-glucaro-1,4-lactone, which inhibits bacterial beta-glucuronidase in the gut and so reduces the deconjugation of glucuronidated hormones and xenobiotics before they are excreted. DIM works upstream, shifting which hydroxylated metabolites are formed in the liver. Phase I direction plus phase II retention is why they are so often paired.

Catechol-O-methyltransferase is a magnesium-dependent enzyme, and it is the step that methylates catechol oestrogens such as 4-hydroxyoestrone into their less reactive methoxy forms. DIM shifts oestrogen hydroxylation toward the 2-hydroxy route. Adequate magnesium is what lets the downstream methylation keep pace, which is settled enzymology rather than a trial finding.

S-adenosylmethionine is the methyl donor COMT uses to methylate catechol metabolites. Every methylation draws on that pool. DIM changes the mix of hydroxylated metabolites presented to that step, so methyl group supply is the relevant partner variable.

Betaine remethylates homocysteine to methionine, replenishing the SAM pool that catechol methylation consumes. It is one of the two remethylation routes and does not require B12. That makes it a straightforward partner where methylation capacity is the concern.

5-methyltetrahydrofolate feeds the B12-dependent remethylation of homocysteine to methionine, sustaining SAM production. Without it the methyl supply for COMT tightens. This is textbook one-carbon metabolism and needs no combination study.

Methionine synthase needs methylcobalamin to transfer the folate methyl group to homocysteine. It is the hinge between the folate cycle and the methionine cycle. Its relevance alongside DIM is entirely about maintaining methylation capacity downstream.

Pyridoxal-5-phosphate is the cofactor for the transsulfuration enzymes that route homocysteine into cysteine and onward to glutathione. Glutathione conjugation is one of the routes by which reactive catechol metabolites are cleared. B6 enables that limb.

N-acetylcysteine supplies cysteine, the limiting substrate for glutathione synthesis. Glutathione S-transferases conjugate reactive quinones formed from catechol metabolites, which is a phase II clearance route. DIM changes what arrives at that step, so substrate supply matters.

Glutathione is the conjugating nucleophile for reactive electrophiles including quinones derived from catechol oestrogens. Oral glutathione absorption is limited and debated, which is why cysteine donors are often used instead. The pathway relevance is established even where the oral form's contribution is not.

Silymarin influences hepatic phase I and phase II enzyme activity in laboratory and animal work, the same broad territory in which DIM acts as an AhR ligand inducing CYP1A enzymes. Two agents nudging hepatic enzyme activity in one regimen is worth flagging for anyone on prescription medicines cleared by those enzymes. No human study of the combination is available here.

Gut bacterial beta-glucuronidase deconjugates glucuronidated hormones in the colon and returns them to circulation, and the size of that activity varies with the microbiome. A review of cruciferous metabolites specifically identifies the microbiome as a source of between-person variation in what these compounds do. Which strains shift that activity in which direction is not settled, so this is a modulating relationship rather than a directional claim.

Soluble fibre shortens colonic transit and binds bile acids and steroid conjugates, reducing the window for bacterial deconjugation and reabsorption. That is a plausible complement to DIM's upstream effect on which metabolites form. Fibre in the same dose can also slow absorption of a lipophilic compound like DIM, so spacing is sensible.

DIM is highly lipophilic and poorly water soluble, so fat in the same meal improves its dissolution and absorption. Flax also carries lignans that gut bacteria convert to weakly receptor-active enterolignans, which is a separate mechanism from anything DIM does. Ground flax rather than the pressed oil is where the lignans sit.

Medium-chain triglycerides provide a lipid phase that dissolves poorly water soluble actives and triggers bile release. Unformulated crystalline DIM is notoriously poorly absorbed for exactly that reason. A lipid vehicle is one of the standard answers, alongside microencapsulation.

Phospholipids form mixed micelles with bile salts and are used to disperse lipophilic actives into an absorbable form. Several enhanced-absorption DIM preparations are built on phospholipid or emulsifier systems for that reason. The mechanism is formulation physics, not a pharmacological interaction.

Tocopherol and its polyethylene glycol succinate derivative are used as solubilisers and carriers for poorly soluble actives, and vitamin E appears in commercial enhanced-absorption DIM as part of that system. It also protects the lipid phase from oxidation during shelf life. Its role here is as a vehicle component rather than as an active partner.

Piperine inhibits intestinal and hepatic glucuronidation and some CYP activity, which raises systemic exposure to a number of co-ingested compounds. Since DIM is itself an inducer of CYP1A enzymes, pairing the two puts an inhibitor and an inducer in the same capsule. The net direction has not been measured for DIM, which is why this is flagged rather than recommended.

Curcumin activates Nrf2 and modulates phase II enzyme expression in cell work, complementing DIM's activity at the aryl hydrocarbon receptor on the phase I side. Both are lipophilic and both are poorly absorbed unformulated. The overlap is pathway-level and demonstrated in laboratory systems, not in a human combination trial.

Resveratrol interacts with oestrogen receptors and with enzymes of steroid metabolism in laboratory preparations, giving it a foot in the same pathway DIM affects. Whether the two push in the same direction in people has not been measured. Keep this as a mechanistic lead.

Nuclear receptors, including the steroid receptors, depend on zinc-finger domains for DNA binding, and zinc is a cofactor across the enzymes of hormone metabolism. That is background requirement rather than a specific interaction with DIM. It belongs in the same formula as a supporting nutrient, not as a partner acting on DIM.

Selenium is required as selenocysteine in glutathione peroxidases, which handle peroxides generated during oxidative metabolism of catechols. That places it downstream of the metabolic shift DIM produces. Established cofactor biochemistry, no combination study needed.

Vitamin D acts through its own nuclear receptor and is routinely included in hormone-support formulas alongside DIM. The two receptors are different and no shared step has been shown. This is co-formulation convention worth stating plainly as such.